Upset by Big Pharma practices, some large American hospitals launch locally based non-profit generic drug companies - increasing competition equals industrial paradigm shifts, economic benefits for patients, and reduced impact from any shortages. Is this an omen of things to come?https://lnkd.in/g9S53s3
Univercells secures €3M Series A2 funding.
This capital injection will help accelerate the development and commercialization of the company’s technology platforms and innovative solutions. Read the full Press Release: https://lnkd.in/dfJ_anD
Univercells in Pharmaceutical Technology
Read about 'Accelerating Vaccines Development and Manufacturing' with insights from UNIVERCELLS Chief Technology Officer, Jose Castillo, one of the reference innovators in the field: https://goo.gl/dq39Es
[Market Trend] Magistral preparations for Orphan DrugsIn Belgium, pharmacists are granted authorization to prepare a selection of orphan drugs for rare diseases treatment, increasing their accessibility for patients.
Such magistral preparations bring an alternative to the standard high production costs triggered by low-incidence diseases, offering a 10-fold decrease in treatment price.
First implemented for chemical drugs, this regulation could be considered for biologics - with appropriate small-scale production and quality control solution - and benefits even more patients suffering from rare diseases.
Read the full article (French): https://lnkd.in/eF7ysdE
#BELIND2017 Hugues Bultot, CEO of Univercells, joins the Belgian State Visit to India. Following a first seminar on Personnalised Healthcare for All held in New Delhi, Mr. Bultot will participate in the Life Sciences and Healthcare Seminar in Mumbai - Nov 9. Read more: https://lnkd.in/ec2yHWEWallonia Foreign Trade and Investment Agency (AWEX) Awex India Brussels Invest & Export Flanders Investment & Trade (FIT)